1001547-76-7

Upstream product

• 54522-28-0 (3R,3aS,6S,6aS)-hexahydrofuro[3,2-b]furan-3,6-diyl bis(4-methylbenzenesulfonate) 
• 652-67-5 Isosorbide 
• 161458-58-8 (2S,1'S)-(-)-2-<2-Hydroxy-1-(p-toluenesulfonyloxy)ethyl>-2,5-dihydrofuran 
• 1001547-72-3 (3S,3aS,6S,6aS)-6-bromohexahydrofuro[3,2-b]furan-3-yI 4-methylbenzenesulfonate 
• 501-53-1 benzyl chloroformate 
• 1001548-21-5 (R)-2-amino-1-[(S)-2,5-dihydrofuran-2-yl]ethanol 
• 1001548-20-4 (S)-2-amino-1-[(S)-2,5-dihydrofuran-2-yl]ethanol 

Downstream Products

• 1001660-66-7 benzyl (R)-2-((S)-2,5-dihydrofuran-2-yl)-2-methoxyethyl carbamate 
• 1001548-17-9 (3R,3aR,6R,6aS)-3-hydroxyhexahydro-2H-furo[3,2-b]pyrrol-6-yl 4-methylbenzenesulfonate 
• 1001547-84-7 (3R,3aR,6R,6aS)-tert-butyl 3-hydroxy-6-(tosyloxy)tetrahydro-2H-furo[3,2-b]pyrroIe-4(5H)-carboxylate 
• 1001547-81-4 C₂₁H₂₃NO₇S 
• 1001614-46-5 N-((S)-1-((3R,3aR,6aR)-3-hydroxydihydro-2H-furo[3,2-b]pyrrol-4(5H,6H,6aH)-yl)-4,4-dimethyl-1-oxopentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide 
• 1172139-86-4 (3R,3aR,6R,6aS)-3-hydroxyhexahydro-2H-furo[3.2-b]pyrrol-6-yl 4-methylbenzenesulfonate hydrochloride 
• 1001548-04-4 (3R,3aR,6S,6aS)-benzyl 6-chloro-3-hydroxytetrahydro-2H-furo[3,2-b]pyrrole-4(5H)-carboxylate 
• 1001547-86-9 (3R,3aR,6R,6aS)-benzyl 3-hydroxy-6-(tosyloxy)tetrahydro-2H-furo[3,2-b] pyrrole-4(5H)-carboxylate 
• 1001660-48-5 benzyl (R)-2-tert-butoxy-2-((S)-2,5-dihydrofuran-2-yl)ethyl carbamate 
• 1001547-78-9 (R)-2-(benzyloxycarbonylamino)-1-((S)-2,5-dihydrofuran-2-yI) ethyl 4-methyl benzenesulfonate 

Relevant academic research and scientific papers

FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R3 and R4 is H, and the other is selected from C1-6-alkyl,

TETRAHYDROFURO [3, 2-B] PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEASES

A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein one of R1 and R2 is H, and the other is selected fromC1-8-alkyl, C3-6-cycloalkyl and C1-8/sub

TETRAHYDROFURO [3, 2-B] PYRR0L-3-0NE INTERMEDIATES

The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound

FURO [3, 2-B] PYRROL DERIVATIVES

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R3 is tert-butylmethyl, sec-butyl or tert-butyl; X is CH or N; and R4 is optionally substituted C1-8 alkyl